A retrospective study on the efficacy of different chemotherapy regimens in lung adenocarcinoma patients harboring common EGFR mutations
10.3969/j.issn.1000-8179.2020.09.429
- VernacularTitle: 不同化疗方案治疗 EGFR 常见突变肺腺癌疗效的回顾性研究
- Author:
Xuewu WEI
1
Author Information
1. Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology
- Publication Type:Journal Article
- Keywords:
Chemotherapy;
Efficacy;
EGFR mutation;
Lung adenocarcinoma
- From:
Chinese Journal of Clinical Oncology
2020;47(9):450-453
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate an optimal chemotherapy regimen for patients diagnosed with lung adenocarcinoma harboring common EGFR mutations. Methods: Clinical data of 4,021 patients diagnosed with advanced primary lung adenocarcinoma who were admitted to Guangdong Lung Cancer Institute from June 2007 to June 2014 were retrospectively collected. The efficacy of the standard chemotherapy regimen in patients diagnosed with luny adenocarcinoma harboring common EGFR mutations was analyzed. Results: In total, 205 patients were included in the study, and 119, 60 and 81 patients received gemcitabine plus platinum, pemetrexed plus platinum, and paclitaxel plus platinum regimens, respectively. Statistical difference was not observed in the objective response rate (ORR,25.2%, 25.0%, 30.8%, respectively) and progression free survival (PFS, 5.5, 5.2, 6.2 months, respectively) between these three treatment regimens (P=0.979, P=0.811). Conclusions: Platinum-based chemotherapy regimens based on gemcitabine, pemetrexed, and paclitaxel have similar efficacy in patients diagnosed with advanced primary lung adenocarcinoma harboring common EGFR mutations.
